Opzelura (Ruxolitinib Phosphate) Patent Expiration, LOE Window & CMS Spending

Opzelura (Ruxolitinib Phosphate) by Incyte: FDA Orange Book core substance LOE 2028-12-12 (last listed 2041-05-05), 0 AB generics, $230.1M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorIncyte
FDA Application & PathwayN215309 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2028-12-12
Last Listed Patent or Exclusivity Date2041-05-05
Orange Book Patents (*PED Extensions)33 patents (11 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$230.1M
2024 Medicare Part D Spend$105.9M
2024 Medicaid Spend$124.2M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Incyte across sibling Meru public-data platforms.